Cancer Genomics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 18.9 billion
Estimated Base Value
2035 Forecast
US$ 59.2 billion
Projected Market Value
CAGR 2026–2035
12.1%
Compound Annual Growth
Largest Segment
Genomic Sequencing Services
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
Guardant Health
Emerging Players
Freenome, Ultima Genomics
Cancer Genomics Market Overview
The Cancer Genomics Market focuses on applying genomic technologies and bioinformatics to analyze the genetic and molecular basis of cancer, supporting precision medicine. This market encompasses products, services, and research activities designed to identify specific genomic alterations within tumor cells or circulating tumor DNA. It is crucial for enhancing cancer diagnosis, prognosis, treatment selection, and monitoring, driving the development of targeted therapies and companion diagnostics. Key users include pharmaceutical companies, biotechnology firms, diagnostic laboratories, and research institutions, all working to personalize cancer care and improve patient outcomes.
The Cancer Genomics Market is estimated at $18.9 Bn in 2025 and is forecast to reach $59.2 Bn in 2035, growing at a CAGR of 12.1% from 2025 to 2035. Market expansion is driven by the rising global incidence of various cancer types, advancements in genomic sequencing technologies, increased R&D spending by pharmaceutical companies, and growing awareness of precision medicine benefits. However, high costs of genomic sequencing, complex data interpretation, regulatory hurdles, and limited reimbursement policies restrain broader adoption.
The market is segmented by Type (Genomic Sequencing Services, Genomic Profiling & Testing Services, Bioinformatics Solutions, Consumables & Reagents, Instruments & Equipment, Liquid Biopsy Products & Services, Cancer Genomic Databases & Knowledgebases), Technology (Next-Generation Sequencing, Microarray Technology, Quantitative Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Sanger Sequencing, Mass Spectrometry, Others), Application (Clinical Oncology Diagnostics, Therapeutic Decision Making, Prognostics & Disease Monitoring, Drug Discovery & Development, Biomarker Discovery, Cancer Screening & Early Detection, Basic & Translational Research), End-User (Hospitals & Oncology Clinics, Diagnostic Laboratories, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Government & Regulatory Bodies), Workflow Stage (Sample Preparation, Library Preparation & Target Enrichment, Sequencing & Data Generation, Primary Data Analysis, Secondary Data Analysis & Interpretation, Reporting & Clinical Decision Support, Data Management & Storage), and Omics Type (Genomics, Transcriptomics, Epigenomics, Proteomics, Spatial Omics, Single-Cell Omics, Multi-Omics Integration). Leading companies include Guardant Health, Exact Sciences, Tempus, Natera, Caris Life Sciences, Qiagen, 10x Genomics, Myriad Genetics, GRAIL, Adaptive Biotechnologies, PacBio (Pacific Biosciences), and Personalis. The full report covers these segments across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Market Definition & Overview
The Cancer Genomics Market focuses on the application of genomic technologies and bioinformatics to analyze the genetic and molecular basis of cancer, facilitating precision medicine. It encompasses products, services, and research activities aimed at identifying specific genomic alterations within tumor cells or circulating tumor DNA. This market is crucial for enhanced cancer diagnosis, prognosis, treatment selection, and monitoring, driving the development of targeted therapies and companion diagnostics. Key technologies include next-generation sequencing (NGS), microarrays, and real-time PCR, utilized by pharmaceutical companies, biotechnology firms, diagnostic laboratories, and research institutions to personalize cancer care and improve patient outcomes.
Scope
- Global geographic coverage including North America, Europe, Asia Pacific, and ROW.
- Segmentation by technology, application, and end-user segments.
- Analysis of the market from the historical period through a specific forecast period (2025-2035).
Inclusions
- Next-generation sequencing (NGS) platforms, reagents, and services specific to cancer.
- Cancer-specific gene panels, genomic profiling kits, and liquid biopsy assays.
- Bioinformatics software and data analysis services for cancer genomic data.
- Companion diagnostics for oncology drugs based on genomic biomarkers.
- Research and development activities for genomic-driven cancer therapies.
Exclusions
- Non-genomic cancer diagnostic methods like traditional imaging or general pathology.
- Generic or non-cancer related human genomics research or consumer testing.
- General pharmaceutical drug discovery not directly linked to genomic biomarkers.
- Basic academic research in genetics without commercial product development.
- Veterinary or non-human cancer genomics applications.
Market Size Forecast
Executive Summary
• The Cancer Genomics market is valued at $18.9 Bn in 2025 and is forecast to reach $59.2 Bn by 2035, reflecting a robust CAGR of 12.1% as demand accelerates across every major segment and region over the ten-year outlook.
• Genomic Sequencing Services leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Strategic partnerships and M&A activity are accelerating, driven by the need for integrated multi-omics platforms and advanced AI-driven analytical capabilities, reshaping the competitive landscape globally.
• Expanding clinical utility and improving reimbursement policies for genomic testing, especially liquid biopsies, are pivotal growth catalysts, driving wider adoption across diverse cancer types and healthcare systems.
• Investment is surging into early cancer detection and minimal residual disease (MRD) monitoring, particularly in APAC and North America, signaling a paradigm shift toward proactive patient management.
• Next-generation sequencing advancements, coupled with robust bioinformatics infrastructure and standardized data sharing protocols, are crucial for overcoming scalability bottlenecks and maximizing clinical impact worldwide.
• The impending integration of germline and somatic genomic insights promises comprehensive patient stratification, mandating evolving regulatory frameworks and ethical guidelines to ensure equitable access.
• Emerging market penetration and localized data generation initiatives represent key battlegrounds for market share, compelling global players to adapt strategies for diverse healthcare infrastructures.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The Cancer Genomics Market was valued at $18.9 billion in the base year, reflecting its significant foundation within precision medicine.
Future Market Expansion
This market is projected to reach an impressive $59.2 billion by the forecast year, demonstrating substantial growth potential.
Robust Growth Outlook
A strong Compound Annual Growth Rate (CAGR) of 12.1% is anticipated, underscoring the dynamic expansion of cancer genomics solutions.
North American Leadership
North America is expected to remain a leading region in the market, driven by advanced research and high adoption rates of precision medicine technologies.
Diagnostic Testing Dominance
The diagnostic testing segment is projected to hold a leading share, fueled by increasing demand for early detection and personalized treatment selection.
Emerging Liquid Biopsies
The widespread adoption of liquid biopsies represents a notable trend, offering non-invasive methods for cancer detection and monitoring.
Market Dynamics
Market Trends
- AI and machine learning are increasingly integrated for genomic data analysis.
- There is a growing shift towards liquid biopsies for non-invasive cancer detection.
- Personalized cancer therapies based on genomic profiling are gaining traction.
- Multi-omics data integration is enhancing comprehensive patient insights.
Growth Drivers
- The global incidence of various cancer types continues to rise significantly.
- Advancements in genomic sequencing technologies fuel market expansion.
- Increased R&D spending by pharma firms boosts innovation.
- Growing awareness of precision medicine benefits drives adoption.
Restraints
- High costs of genomic sequencing and data analysis limit broader adoption.
- Complex data interpretation and integration into clinical workflows pose significant challenges.
- Regulatory hurdles and lack of standardized protocols hinder market expansion.
- Limited reimbursement policies and patient access restrict market penetration.
Opportunities
- Significant potential exists in expanding into underserved emerging markets.
- Development of novel diagnostic and prognostic biomarkers is promising.
- Strategic partnerships can accelerate drug discovery and development.
- Early cancer detection and risk assessment offer new applications.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Genomic Sequencing ServicesGenomic Profiling & Testing ServicesBioinformatics SolutionsConsumables & ReagentsInstruments & EquipmentLiquid Biopsy Products & ServicesCancer Genomic Databases & Knowledgebases |
| By Technology | Next-Generation SequencingMicroarray TechnologyQuantitative Polymerase Chain ReactionDigital Polymerase Chain ReactionFluorescence in Situ HybridizationSanger SequencingMass SpectrometryOthers |
| By Application | Clinical Oncology DiagnosticsTherapeutic Decision MakingPrognostics & Disease MonitoringDrug Discovery & DevelopmentBiomarker DiscoveryCancer Screening & Early DetectionBasic & Translational Research |
| By End-User | Hospitals & Oncology ClinicsDiagnostic LaboratoriesAcademic & Research InstitutionsPharmaceutical & Biotechnology CompaniesContract Research OrganizationsGovernment & Regulatory Bodies |
| By Workflow Stage | Sample PreparationLibrary Preparation & Target EnrichmentSequencing & Data GenerationPrimary Data AnalysisSecondary Data Analysis & InterpretationReporting & Clinical Decision SupportData Management & Storage |
| By Omics Type | GenomicsTranscriptomicsEpigenomicsProteomicsSpatial OmicsSingle-Cell OmicsMulti-Omics Integration |
Regional Analysis
- North America leads the cancer genomics market due to substantial R&D investments, advanced healthcare infrastructure, and the presence of major pharmaceutical and biotech companies. Favorable reimbursement policies and high adoption rates of precision medicine further bolster its dominant position.
- Asia-Pacific is projected as the fastest-growing region, driven by increasing healthcare expenditure, rising prevalence of cancer, and improving genomics research capabilities. Government initiatives supporting precision medicine and a vast patient pool also contribute significantly.
- European regions are emphasizing integrated genomics data platforms and collaborative research networks to enhance personalized oncology. This trend facilitates better data sharing and clinical trial enrollment, accelerating the translation of genomic discoveries into routine patient care pathways.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominant market driven by extensive R&D, significant investment in genomic research, and well-established precision medicine initiatives.
- High adoption rates are supported by advanced healthcare infrastructure and favorable reimbursement policies.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- An emerging market with significant potential due to improving healthcare infrastructure and rising demand for advanced diagnostic and therapeutic solutions.
- However, challenges include funding limitations and regulatory complexities.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A mature market benefiting from strong academic research, government funding for personalized medicine projects, and increasing public awareness.
- However, regulatory harmonization across diverse countries can pose a challenge.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiencing rapid growth fueled by rising healthcare expenditure, large patient populations, and increasing government support for genomic sequencing projects.
- Countries like China, India, and Japan are key contributors to this expansion.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Growing steadily, particularly in wealthy Gulf nations investing in cutting-edge healthcare technologies and genomics research centers.
- However, accessibility and affordability remain barriers in many parts of Africa.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. remains the dominant market due to extensive R&D investment, high healthcare expenditure, and rapid adoption of advanced genomic technologies in oncology. Strong innovation and a robust regulatory framework further drive market expansion. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | As the largest economy in the region, Brazil has a substantial patient population driving demand for advanced cancer diagnostics and personalized therapies. Increasing private sector investment and awareness are key growth factors. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany boasts a strong pharmaceutical and biotech industry, coupled with robust public health research and high adoption rates of advanced medical technologies. Its advanced healthcare system readily integrates genomic profiling into cancer treatment. |
| 4 | China | US$ XX.X Mn | XX.X% | China experiences rapid growth fueled by massive government investment in biotech, a vast patient population, and increasing clinical adoption of genomic sequencing. The push for domestic innovation and large-scale genomics projects drives its market leadership. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia is driving healthcare transformation under Vision 2030, with substantial government investment in advanced diagnostics and genomics infrastructure for cancer care. Efforts to localize advanced medical services are boosting market growth. |
Countries Covered (26)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Guardant Health | XX.X% | Expand adoption of liquid biopsy for comprehensive genomic profiling and MRD testing across the cancer care continuum. | — | — | Guardant360Guardant RevealGuardant Health AMEA+1 |
| 2 | Exact Sciences | XX.X% | Leverage its established screening and precision oncology platforms to drive early cancer detection and treatment guidance. | — | — | CologuardOncotype DXOncotype DX Breast DCIS Score+1 |
| 3 | Tempus | XX.X% | Integrate multimodal data (genomic, clinical, imaging) with AI to provide precision medicine solutions for cancer and other diseases. | — | — | Tempus xTTempus xFTempus xP+1 |
| 4 | Natera | XX.X% | Focus on high-growth areas like minimal residual disease (MRD) testing and organ transplant rejection monitoring using cfDNA. | — | — | SignateraProsperaPanorama+1 |
| 5 | Caris Life Sciences | XX.X% | Provide comprehensive molecular profiling services that integrate AI to guide precision cancer therapy and drug development. | — | — | Caris Molecular IntelligenceCaris PROFILERCaris MI Exome+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Guardant Health, Exact Sciences, Tempus, Natera, Caris Life Sciences, Qiagen, 10x Genomics, Myriad Genetics, GRAIL, Adaptive Biotechnologies, PacBio (Pacific Biosciences), Personalis, Twist Bioscience, Bio-Rad Laboratories, PerkinElmer, Bio-Techne, SOPHiA GENETICS, Burning Rock Biotech, Novogene, Bionano Genomics
The global Cancer Genomics market features a competitive landscape led by Guardant Health, Exact Sciences, Tempus, Natera, Caris Life Sciences, and Qiagen, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Guardant Health
Exact Sciences
Tempus
Natera
Caris Life Sciences
Qiagen
10x Genomics
Myriad Genetics
GRAIL
Adaptive Biotechnologies
PacBio (Pacific Biosciences)
Personalis
Twist Bioscience
Bio-Rad Laboratories
PerkinElmer
Bio-Techne
SOPHiA GENETICS
Burning Rock Biotech
Novogene
Bionano Genomics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
New Multi-Cancer Liquid Biopsy Test Receives FDA Breakthrough Device Designation
A leading precision oncology firm announced its novel multi-cancer early detection (MCED) liquid biopsy test has received FDA Breakthrough Device designation, paving the way for accelerated review and market entry. This test promises to significantly improve non-invasive early diagnosis across various cancer types.
Pharma Giant Acquires AI-Driven Genomics Analytics Startup for US$ XX.X
A major pharmaceutical company completed the acquisition of an innovative AI genomics startup specializing in predictive biomarker discovery and drug response analysis. This strategic move is expected to bolster the pharma company's drug development pipeline in precision oncology.
Genomics Leader Partners with Major Cancer Center for Pan-Cancer Clinical Trial
A prominent cancer genomics company announced a strategic partnership with a renowned academic cancer center to initiate a large-scale pan-cancer clinical trial. The collaboration aims to validate novel genomic biomarkers and explore combination therapies in diverse patient populations.
Innovative Single-Cell Genomics Firm Secures US$ XX.X Series C Funding
A company at the forefront of single-cell genomics technology successfully closed a US$ XX.X Series C funding round. The investment will accelerate the development and commercialization of its high-resolution platforms for deciphering tumor heterogeneity and microenvironment interactions.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $18.9 Bn |
| Market Size (Forecast) | $59.2 Bn |
| CAGR | 12.1% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 26 Countries |
| Segments Covered | 6 Segments, 42 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Cancer Genomics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The Cancer Genomics market is estimated at $18.9 Bn in 2025. It is forecast to reach $59.2 Bn by 2035, indicating substantial growth over the next decade. This expansion reflects the increasing adoption of genomic technologies in cancer care.
The Cancer Genomics market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 12.1% from 2025 to 2035. This growth is driven by advancements in genomic sequencing and increasing applications in precision oncology.
The main segments include Type, Technology, Application, End-User, Workflow Stage, and Omics Type. These cover areas such as genomic sequencing services, next-generation sequencing, clinical oncology diagnostics, hospitals, sample preparation, and genomics, among others.
Leading companies in the Cancer Genomics market include Guardant Health, Exact Sciences, Tempus, Natera, Caris Life Sciences, Qiagen, 10x Genomics, Myriad Genetics, GRAIL, Adaptive Biotechnologies, PacBio (Pacific Biosciences), and Personalis. These companies offer various products and services in the sector.
The Cancer Genomics market report covers market size and growth forecasts, detailed segmentation by Type, Technology, Application, End-User, Workflow Stage, and Omics Type, and regional analysis across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. It also includes profiles of leading companies.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
AI Clinical Genomics Market
$2.7 Bn in 2025 · 18.7% CAGR
AI for Genomics Research Market
$1.9 Bn in 2025 · 18.3% CAGR
Artificial Intelligence In Genomics Market
$3.1 Bn in 2025 · 19.2% CAGR
Cancer Immunotherapy Market
$228.6 Bn in 2025 · 9.0% CAGR
Clinical Genomics Market
$15.6 Bn in 2025 · 11.3% CAGR
Consumer Genomics Market
$2.1 Bn in 2025 · 21.6% CAGR
Personalized Cancer Vaccines Market
$416.0 Mn in 2025 · 29.0% CAGR
Single Cell Genomics Market
$4.8 Bn in 2025 · 15.7% CAGR